More on REGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $810.31 |
|
|||
| Open | $803.83 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $808.63 | ||||
| Day Low | $796.73 | ||||
| P/E | 211.52 | ||||
| EPS | $3.81 | ||||
| Volume | 220,599 | ||||
- RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
- Form 4 REGENERON PHARMACEUTICAL For: Aug 19 Filed by: LAROSA JOSEPH J
- Form N-PX REGENERON PHARMACEUTICAL For: Jun 30
- Form 4 REGENERON PHARMACEUTICAL For: Aug 18 Filed by: Fenimore Christopher R.
- Regeneron Announces Investor Conference Presentations
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
- Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
- Form 4 REGENERON PHARMACEUTICAL For: Aug 10 Filed by: Guarini Kathryn
- Form 4 REGENERON PHARMACEUTICAL For: Aug 10 Filed by: Zoghbi Huda Y
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
